Non-Hodgkin lymphoma following temozolomide.
Temozolomide (TMZ) is an oral alkylating agent with significant activity against glioblastoma multiforme (GBM) and melanoma. It increases survival by 2.5 months when used in combination with radiotherapy as an adjuvant therapy in GBM. Secondary MDS/AML or non-Hodgkin lymphoma attributed to TMZ exposure has been reported. We report a case of non-Hodgkin lymphoma secondary to temozolomide in a 20-year-old female who was treated for GBM with concurrent TMZ and radiotherapy. She developed lymphoma 2 months after completing chemoradiotherapy. Although she was treated with combination chemotherapy for lymphoma, she died of progressive GBM.
Sharma
Atul
A
Department of Medical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. atul1@hotmail.com
Gupta
Deepak
D
Mohanti
B K
BK
Thulkar
Sanjay
S
Dwary
Amit
A
Goyal
Shikha
S
Muzumder
Sandeep
S
Das
Prasenjit
P
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide